{"transactions":[{"id":884465,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":40651,"derivative":{"underlying":"Common Stock","underlying_shares":40650},"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":884464,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":20682,"price":8.7,"value":179933.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":884463,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":320825,"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":907426,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":82236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":164474,"derivative":{"underlying":"Common Stock","underlying_shares":82236},"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":907425,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":42643,"price":6.93,"value":295515.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":280175,"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":907424,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":82236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":322818,"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":950828,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":45602,"derivative":{"underlying":"Common Stock","underlying_shares":30397},"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":950827,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":15435,"price":1.98,"value":30561.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":240582,"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":950826,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."}],"balance_after":256017,"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":1245770,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":81301,"derivative":{"underlying":"Common Stock","underlying_shares":40650},"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1245769,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":15860,"price":3.42,"value":54241.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":225620,"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1245768,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":241480,"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1271416,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-13T01:16:47.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":843750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 10, 2025."}],"balance_after":843750,"derivative":{"exercise_price":3.39,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":843750},"source":{"system":"sec-edgar","filing":"0001326110-25-000012","document":"wk-form4_1739409401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000012/wk-form4_1739409401.xml","form_type":"4"}},{"id":1271415,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-13T01:16:47.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":246710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":246710,"derivative":{"underlying":"Common Stock","underlying_shares":246710},"source":{"system":"sec-edgar","filing":"0001326110-25-000012","document":"wk-form4_1739409401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000012/wk-form4_1739409401.xml","form_type":"4"}},{"id":1314199,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T21:54:24.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":75999,"derivative":{"underlying":"Common Stock","underlying_shares":30397},"source":{"system":"sec-edgar","filing":"0001326110-25-000003","document":"wk-form4_1735941259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000003/wk-form4_1735941259.xml","form_type":"4"}},{"id":1314198,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:54:24.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":15405,"price":2.56,"value":39436.8,"ownership":{"direct":true},"balance_after":200830,"source":{"system":"sec-edgar","filing":"0001326110-25-000003","document":"wk-form4_1735941259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000003/wk-form4_1735941259.xml","form_type":"4"}},{"id":1314197,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:54:24.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":216235,"source":{"system":"sec-edgar","filing":"0001326110-25-000003","document":"wk-form4_1735941259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000003/wk-form4_1735941259.xml","form_type":"4"}},{"id":1619049,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-26T21:40:11.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":424390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024."}],"balance_after":424390,"derivative":{"exercise_price":5.24,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":424390},"source":{"system":"sec-edgar","filing":"0001326110-24-000026","document":"wk-form4_1708983595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000026/wk-form4_1708983595.xml","form_type":"4"}},{"id":1619048,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-26T21:40:11.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":121951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":121951,"derivative":{"underlying":"Common Stock","underlying_shares":121951},"source":{"system":"sec-edgar","filing":"0001326110-24-000026","document":"wk-form4_1708983595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000026/wk-form4_1708983595.xml","form_type":"4"}},{"id":1661359,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:33:57.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":false,"shares":70745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award  vested on September 1, 2023 and 70,745 of the shares vested on January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award  vested on September 1, 2023 and 70,745 of the shares vested on January 31, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":70745},"source":{"system":"sec-edgar","filing":"0001326110-24-000014","document":"wk-form4_1706920419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000014/wk-form4_1706920419.xml","form_type":"4"}},{"id":1661358,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:33:57.000Z","date":"2024-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":26835,"price":3.36,"value":90165.6,"ownership":{"direct":true},"balance_after":185838,"source":{"system":"sec-edgar","filing":"0001326110-24-000014","document":"wk-form4_1706920419.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000014/wk-form4_1706920419.xml","form_type":"4"}},{"id":1661357,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:33:57.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":true,"shares":70745,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":212673,"source":{"system":"sec-edgar","filing":"0001326110-24-000014","document":"wk-form4_1706920419.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000014/wk-form4_1706920419.xml","form_type":"4"}},{"id":1691686,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-04T02:41:54.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":106396,"derivative":{"underlying":"Common Stock","underlying_shares":30397},"source":{"system":"sec-edgar","filing":"0001326110-24-000008","document":"wk-form4_1704336100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000008/wk-form4_1704336100.xml","form_type":"4"}},{"id":1691685,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-04T02:41:54.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":10511,"price":5.02,"value":52765.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld."}],"balance_after":141928,"source":{"system":"sec-edgar","filing":"0001326110-24-000008","document":"wk-form4_1704336100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000008/wk-form4_1704336100.xml","form_type":"4"}},{"id":1691684,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-04T02:41:54.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":152439,"source":{"system":"sec-edgar","filing":"0001326110-24-000008","document":"wk-form4_1704336100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000008/wk-form4_1704336100.xml","form_type":"4"}},{"id":1786917,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-06T23:41:07.000Z","date":"2023-09-01","kind":"exercise","planned":false,"acquired":false,"shares":70744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024."}],"balance_after":70745,"derivative":{"underlying":"Common Stock","underlying_shares":70744},"source":{"system":"sec-edgar","filing":"0001326110-23-000115","document":"wk-form4_1694043655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000115/wk-form4_1694043655.xml","form_type":"4"}},{"id":1786916,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-06T23:41:07.000Z","date":"2023-09-01","kind":"exercise","planned":false,"acquired":true,"shares":70744,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":122042,"source":{"system":"sec-edgar","filing":"0001326110-23-000115","document":"wk-form4_1694043655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000115/wk-form4_1694043655.xml","form_type":"4"}},{"id":1795172,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-29T00:58:31.000Z","date":"2023-08-25","kind":"grant","planned":false,"acquired":true,"shares":141489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the  award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the  award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024."}],"balance_after":141489,"derivative":{"underlying":"Common Stock","underlying_shares":141489},"source":{"system":"sec-edgar","filing":"0001326110-23-000106","document":"wk-form4_1693270702.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000106/wk-form4_1693270702.xml","form_type":"4"}},{"id":2066700,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-05T02:49:13.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":7598,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":136793,"derivative":{"underlying":"Common Stock","underlying_shares":7598},"source":{"system":"sec-edgar","filing":"0001326110-23-000005","document":"wf-form4_167288693724683.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000005/wf-form4_167288693724683.xml","form_type":"4"}},{"id":2066699,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-05T02:49:13.000Z","date":"2022-12-31","kind":"exercise","acquired":true,"shares":7598,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51298,"source":{"system":"sec-edgar","filing":"0001326110-23-000005","document":"wf-form4_167288693724683.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000005/wf-form4_167288693724683.xml","form_type":"4"}},{"id":2317616,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-26T01:05:21.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Issuer's attainment of a financial goal for fiscal year 2022, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date. The vesting commencement date for this option is March 23, 2022."}],"balance_after":125000,"derivative":{"exercise_price":5.83,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001326110-22-000021","document":"wf-form4_164825670608866.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000021/wf-form4_164825670608866.xml","form_type":"4"}},{"id":2317615,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-26T01:05:21.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022."}],"balance_after":125000,"derivative":{"exercise_price":5.83,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001326110-22-000021","document":"wf-form4_164825670608866.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000021/wf-form4_164825670608866.xml","form_type":"4"}},{"id":2475296,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-13T21:15:40.000Z","date":"2021-12-09","kind":"exercise","acquired":false,"shares":17242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"17,242 of the restricted stock units (\"RSUs\") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"17,242 of the restricted stock units (\"RSUs\") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026."}],"balance_after":144391,"derivative":{"underlying":"Common Stock","underlying_shares":17242},"source":{"system":"sec-edgar","filing":"0001326110-21-000012","document":"wf-form4_163943012212741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611021000012/wf-form4_163943012212741.xml","form_type":"4"}},{"id":2475295,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-13T21:15:40.000Z","date":"2021-12-09","kind":"exercise","acquired":true,"shares":17242,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43700,"source":{"system":"sec-edgar","filing":"0001326110-21-000012","document":"wf-form4_163943012212741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611021000012/wf-form4_163943012212741.xml","form_type":"4"}},{"id":2571880,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-14T00:34:24.000Z","date":"2021-09-09","kind":"exercise","acquired":false,"shares":7598,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"17,242 of the restricted stock units (\"RSUs\") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"17,242 of the restricted stock units (\"RSUs\") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026."}],"balance_after":161633,"derivative":{"underlying":"Common Stock","underlying_shares":7598},"source":{"system":"sec-edgar","filing":"0001209191-21-055786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121055786/doc4.xml","form_type":"4"}},{"id":2571879,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-14T00:34:24.000Z","date":"2021-09-09","kind":"exercise","acquired":true,"shares":7598,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."}],"balance_after":26458,"source":{"system":"sec-edgar","filing":"0001209191-21-055786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121055786/doc4.xml","form_type":"4"}}]}